Ionix Pharmaceuticals Ltd.

Cambridge-based biotech Bicycle Therapeutics has appointed Andy Sandham as non-executive chairman. Mr Sandham held previous roles at Cantab Pharmaceuticals, Hexagen, Signature BioScience and Ionix Pha

A £20 million series A equity financing by The Wellcome Trust's investment division has given Kymab, a spin-out from the Trust's Sanger Institute in Cambridge, UK, the financial means to "build a subs

Europe's summertime flurry of private biotech sell-offs points to growing pragmatism among management and VCs, and still-poor valuations on the public markets. Firms which haven't already considered t

Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain. By Mel